DHA supplementation reduces Alzheimer's disease risk, particularly in ApoE4 carriers
Summary
Observational cohorts (Framingham, CHS, Rotterdam) consistently associate higher plasma/dietary DHA with lower dementia risk, and mechanistic work shows ApoE4 carriers have impaired brain DHA transport across the blood-brain barrier, providing biological plausibility for greater benefit in that subgroup. However, RCT evidence is mixed: the ADCS DHA trial (Quinn 2010) found no benefit in mild-to-moderate AD, while the PreventE4 trial (Yassine 2024) showed DHA raised brain DHA more in ApoE4 carriers but clinical outcomes remain preliminary. The MAPT trial found no cognitive benefit of omega-3 alone. Current evidence supports modest associations and biological plausibility but falls short of establishing DHA deficiency as causal for AD or DHA supplementation as preventive.
Five-score assessment
Scope
- established moderate-to-severe Alzheimer's dementia treatment
- claims of disease reversal
- non-ApoE4 populations as a primary prevention strategy
Evidence sources
Supporting (2)
-
High-dose DHA raised CSF DHA, with blunted but measurable response in ApoE4 carriers, supporting the ApoE4-DHA transport mechanism.
-
Observational and mechanistic synthesis supporting DHA-ApoE4 interaction and greater potential benefit if dosed before cognitive symptoms.
Contradicting (2)
-
2g/day DHA for 18 months did not slow cognitive or functional decline in mild-to-moderate AD.
-
No convincing evidence that omega-3 PUFA supplementation prevents cognitive decline or dementia in cognitively healthy older adults.
Neutral / context (1)
-
No dietary supplement, including omega-3/DHA, is recommended for preventing or treating Alzheimer's disease.